1. Home
  2. FSEA vs SPRO Comparison

FSEA vs SPRO Comparison

Compare FSEA & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSEA
  • SPRO
  • Stock Information
  • Founded
  • FSEA 1890
  • SPRO 2013
  • Country
  • FSEA United States
  • SPRO United States
  • Employees
  • FSEA N/A
  • SPRO 46
  • Industry
  • FSEA Savings Institutions
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • FSEA Finance
  • SPRO Health Care
  • Exchange
  • FSEA Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • FSEA 43.6M
  • SPRO 49.6M
  • IPO Year
  • FSEA N/A
  • SPRO 2017
  • Fundamental
  • Price
  • FSEA $9.96
  • SPRO $0.91
  • Analyst Decision
  • FSEA
  • SPRO Buy
  • Analyst Count
  • FSEA 0
  • SPRO 4
  • Target Price
  • FSEA N/A
  • SPRO $5.00
  • AVG Volume (30 Days)
  • FSEA 5.9K
  • SPRO 292.3K
  • Earning Date
  • FSEA 11-08-2024
  • SPRO 03-12-2025
  • Dividend Yield
  • FSEA N/A
  • SPRO N/A
  • EPS Growth
  • FSEA N/A
  • SPRO N/A
  • EPS
  • FSEA N/A
  • SPRO 0.06
  • Revenue
  • FSEA $11,390,000.00
  • SPRO $106,455,000.00
  • Revenue This Year
  • FSEA N/A
  • SPRO N/A
  • Revenue Next Year
  • FSEA N/A
  • SPRO N/A
  • P/E Ratio
  • FSEA N/A
  • SPRO $14.06
  • Revenue Growth
  • FSEA N/A
  • SPRO 37.01
  • 52 Week Low
  • FSEA $8.05
  • SPRO $0.83
  • 52 Week High
  • FSEA $10.38
  • SPRO $1.89
  • Technical
  • Relative Strength Index (RSI)
  • FSEA 55.91
  • SPRO 38.70
  • Support Level
  • FSEA $9.53
  • SPRO $0.83
  • Resistance Level
  • FSEA $10.09
  • SPRO $1.13
  • Average True Range (ATR)
  • FSEA 0.16
  • SPRO 0.07
  • MACD
  • FSEA -0.03
  • SPRO -0.01
  • Stochastic Oscillator
  • FSEA 54.90
  • SPRO 26.67

About FSEA First Seacoast Bancorp Inc.

First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities and bank-owned life insurance.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: